Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 5/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 1/20 | 0.33 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5077985 | 0.87 | CA12 (0.40) | LPAR3LPAR2LPAR1CA12CA1 | |
| SCHEMBL19315879 | 0.86 | CA12 (0.33) | LPAR3LPAR2LPAR1CA12CA1 | |
| Hydrochloric Acid SCHEMBL28609025 | 0.86 | CA12 (0.39) | CA12CA1CA2CA9MVD | |
| SCHEMBL15833400 | 0.83 | CA12 (0.37) | LPAR3LPAR2LPAR1CA12CA1 | |
| SCHEMBL17036893 | 0.83 | CA12 (0.37) | LPAR3LPAR2LPAR1CA12CA1 | |
| SCHEMBL28587893 | 0.78 | CA12 (0.41) | LPAR3LPAR2LPAR1CA12CA1 | |
| SCHEMBL19249018 | 0.75 | — | — | |
| SCHEMBL16647480 | 0.74 | — | — | |
| SCHEMBL14086322 | 0.73 | CA12 (0.40) | CA12CA1CA2CA9 | |
| SCHEMBL23997644 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | FUJIFILM CORPORATION (JP) | 2018-08-28 | — | — | US | disclosed |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORPORATION (JP) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10059734-B2 | Thionucleoside derivative or salt thereof, and pharmaceutical composition | SLC11A2, RNASE1, TYMP | LPAR3 763/4885LPAR2 2043/4885LPAR1 1477/4885 |
| US-20170233429-A1 | THIONUCLEOSIDE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION | SLC11A2, RNASE1, TYMP | LPAR3 763/4885LPAR2 2043/4885LPAR1 1477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.